Generic Name

Orlistat

Precaution

Patient w/ history of hyperoxaluria or Ca oxalate nephrolithiasis. Monitoring Parameters Monitor BMI, diet, LFT, serum glucose (in patient w/ DM), thryroid function (in patient w/ thyroid disease). Lactation: Not recommended; not known if orlistat is distributed in breast milk

Indication

Obesity

Contra Indication

Chronic malabsorption syndrome. Cholestasis. Lactation

Dose

N/A

Side Effect

1-10% Oily spotting (5%) Frequency Not Defined Faecal urgency and incontinence, flatulence, fatty stools or discharge, increased defecation; headache, anxiety, fatigue, menstrual irregularities; abdominal pain/discomfort. Potentially Fatal: Anaphylaxis; angioedema.

Pregnancy Category

Mode of Action

Orlistat is a reversible gastric and pancreatic lipase inhibitor. It exerts antiobesity effects by limiting the absorption of dietary fats through inhibition of triglyceride hydrolysis. It does not exert appetite suppressant effects.

Interaction

May decrease absorption of oral fat-soluble vitamins, amiodarone, propafenone. May decrease plasma levels of ciclosporin. May alter the effects of warfarin (monitor INR). May elevate plasma levels of pravastatin.

Pregnancy Category Note

N/A

Adult Dose

Oral Obesity Adult: Indicated in patients with pretreatment BMI >30 kg/m², or BMI >27 kg/m² in presence of other risk factors or diseases (eg, HTN, DM, hyperlipidemia) 120 mg tid w/ each main meal. Patients w/ BMI >28 kg/m2 irrespective of any risk factors: 60 mg tid. Omit dose if a meal is missed or contains no fat. Discontinue if patient is unable to lose at least 5% of the body wt during the 1st 12 wk of therapy.

Child Dose

<12 years: Safety and efficacy not established

Renal Dose

N/A

Administration

Should be taken with food. Take immediately before or during or up to 1 hr after each main meal. If a meal is missed or contains no fat, the dose may be omitted.